Literature DB >> 10450765

Suitable DNA isolation method for the detection of minimal residual disease by PCR techniques.

O J Verhagen, A J Wijkhuijs, A J van der Sluijs-Gelling, T Szczepański, B E van der Linden-Schrever, M J Pongers-Willemse, E R van Wering, J J van Dongen, C E van der Schoot.   

Abstract

Mesh：

Year:  1999        PMID： 10450765     DOI： 10.1038/sj.leu.2401451

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  5 in total

1.  XLA patients with BTK splice-site mutations produce low levels of wild-type BTK transcripts.

Authors:  Jeroen G Noordzij; Sandra de Bruin-Versteeg; Nico G Hartwig; Corry M R Weemaes; Egbert J A Gerritsen; Eva Bernatowska; Stefaan van Lierde; Ronald de Groot; Jacques J M van Dongen
Journal:  J Clin Immunol       Date:  2002-09       Impact factor: 8.317

Review 2.  The QPCR assay for analysis of mitochondrial DNA damage, repair, and relative copy number.

Authors:  Senyene E Hunter; Dawoon Jung; Richard T Di Giulio; Joel N Meyer
Journal:  Methods       Date:  2010-02-01       Impact factor: 3.608

3.  In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties.

Authors:  Christoph le Viseur; Marc Hotfilder; Simon Bomken; Kerrie Wilson; Silja Röttgers; André Schrauder; Annegret Rosemann; Julie Irving; Ronald W Stam; Leonard D Shultz; Jochen Harbott; Heribert Jürgens; Martin Schrappe; Rob Pieters; Josef Vormoor
Journal:  Cancer Cell       Date:  2008-07-08       Impact factor: 31.743

4.  Two patients with complete defects in interferon gamma receptor-dependent signaling.

Authors:  Jeroen G Noordzij; Nico G Hartwig; Frank A W Verreck; Sandra De Bruin-Versteeg; Tjitske De Boer; Jaap T Van Dissel; Ronald De Groot; Tom H M Ottenhoff; Jacques J M Van Dongen
Journal:  J Clin Immunol       Date:  2007-05-21       Impact factor: 8.317

5.  ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.

Authors:  Michael Merker; Juliane Wagner; Hermann Kreyenberg; Catrin Heim; Laura M Moser; Winfried S Wels; Halvard Bonig; Zoltán Ivics; Evelyn Ullrich; Thomas Klingebiel; Peter Bader; Eva Rettinger
Journal:  Front Immunol       Date:  2020-10-19       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.